Under terms of the agreement, Labopharm will supply Grunenthal with finished packaged product and will receive revenue from sales at rates in proportion with those of previous licensing and distribution agreements that Labopharm has entered into for other European markets.
“With this agreement, we have now secured marketing partners for 22 European countries, which, combined, account for more than 90% of tramadol product sales in Europe,” said James Howard-Tripp, president and CEO, Labopharm. “This agreement builds on our relationship with Grunenthal, the original developer of tramadol and one of our two partners for France.”
According to Labopharm, Grunenthal is the largest marketer of tramadol products in Belgium with a market share of more than 50%.